# Sensei Biotherapeutics Announces Name Change to Faeth Therapeutics, Focused on Advancing PIKTOR, an Oral Therapy Targeting One of the Most Frequently Altered Pathways in Cancer
Canonical URL: https://biopharmsignal.com/news/SNSE/sensei-biotherapeutics-announces-name-change-to-faeth-therapeutics-focused-on-advancing-piktor-an-oral-therapy-targeting-one-of-the-most-frequently-altered-pathways-in-cancer
Ticker: SNSE
Company: Sensei Biotherapeutics
Source: Sensei Biotherapeutics
Published: 2026-06-25 13:46 EST
Original Source URL: https://investors.senseibio.com
## Summary

— Stockholders approved conversion of the Series B preferred stock issued in the February 2026 acquisition of Faeth Therapeutics and concurrent private placement — — Company changed name to Faeth Therapeutics, Inc. on June 15, 2026; common stock expected to begin trading under the ticker symbol

## Article Body
— Stockholders approved conversion of the Series B preferred stock issued in the February 2026 acquisition of Faeth Therapeutics and concurrent private placement — — Company changed name to Faeth Therapeutics, Inc. on June 15, 2026; common stock expected to begin trading under the ticker symbol
## Recent Company News
- 2026-06-25 13:46 EST — [Sensei Biotherapeutics Announces Name Change to Faeth Therapeutics, Focused on Advancing PIKTOR, an Oral Therapy Targeting One of the Most Frequently Altered Pathways in Cancer](https://biopharmsignal.com/news/SNSE/sensei-biotherapeutics-announces-name-change-to-faeth-therapeutics-focused-on-advancing-piktor-an-oral-therapy-targeting-one-of-the-most-frequently-altered-pathways-in-cancer) — Source: Sensei Biotherapeutics
- 2026-06-25 13:46 EST — [Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/SNSE/sensei-biotherapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update) — Source: Sensei Biotherapeutics
- 2026-06-25 13:46 EST — [Sensei Biotherapeutics to Host Virtual KOL Event to Discuss Full Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors on October 20, 2025](https://biopharmsignal.com/news/SNSE/sensei-biotherapeutics-to-host-virtual-kol-event-to-discuss-full-dose-expansion-data-for-solnerstotug-in-pd-l-1-resistant-tumors-on-october-20-2025) — Source: Sensei Biotherapeutics
- 2026-06-25 13:46 EST — [Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025](https://biopharmsignal.com/news/SNSE/sensei-biotherapeutics-reports-new-clinical-results-highlighting-durable-progression-free-survival-data-for-solnerstotug-in-pd-l-1-resistant-tumors-at-the-esmo-congress-2025) — Source: Sensei Biotherapeutics
- 2026-06-25 13:46 EST — [Sensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder Value](https://biopharmsignal.com/news/SNSE/sensei-biotherapeutics-announces-initiation-of-strategic-review-to-maximize-shareholder-value) — Source: Sensei Biotherapeutics
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)